I mistakenly believed that Bioasis was to focus on the acquired Cresence, Phase 2 Ready, Rare Orphan EGF Assets in combination with the Bioasis xB3 platform. I don't see that happening anytime soon with little to no funds in the treasury. Or am I wrong?

https://www.bioasis.us/bioasis-acquires-phase-2-ready-rare-orphan-egf-assets/

Koo